Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8SV9

Crystal structure of ULK1 kinase domain with inhibitor MR-2088

Summary for 8SV9
Entry DOI10.2210/pdb8sv9/pdb
DescriptorSerine/threonine-protein kinase ULK1, (4P)-4-[(2P)-2-(1,2,5,6-tetrahydropyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N-(2,2,2-trifluoroethyl)thiophene-2-carboxamide, SULFATE ION, ... (5 entities in total)
Functional Keywordsautophagy, inhibitor, complex, kinase, transferase, transferase-inhibitor complex, transferase/inhibitor
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight65735.31
Authors
Schonbrunn, E.,Sun, L. (deposition date: 2023-05-15, release date: 2024-03-27, Last modification date: 2024-11-13)
Primary citationMorozova, A.,Chan, S.C.,Bayle, S.,Sun, L.,Grassie, D.,Iermolaieva, A.,Kalaga, M.N.,Frydman, S.,Sansil, S.,Schonbrunn, E.,Duckett, D.,Monastyrskyi, A.
Development of potent and selective ULK1/2 inhibitors based on 7-azaindole scaffold with favorable in vivo properties.
Eur.J.Med.Chem., 266:116101-116101, 2024
Cited by
PubMed Abstract: The UNC-51-like kinase-1 (ULK1) is one of the central upstream regulators of the autophagy pathway, represents a key target for the development of molecular probes to abrogate autophagy and explore potential therapeutic avenues. Here we report the discovery, structure-activity and structure-property relationships of selective, potent, and cell-active ULK1/2 inhibitors based on a 7-azaindole scaffold. Using structure-based drug design, we have developed a series of analogs with excellent binding affinity and biochemical activity against ULK1/2 (IC < 25 nM). The validation of cellular target engagement for these compounds was achieved through the employment of the ULK1 NanoBRET intracellular kinase assay. Notably, we have successfully solved the crystal structure of the lead compound, MR-2088, bound to the active site of ULK1. Moreover, the combination treatment of MR-2088 with known KRAS→RAF→MEK→ERK pathway inhibitors, such as trametinib, showed promising synergistic effect in vitro using H2030 (KRAS) cell lines. Lastly, our findings underscore MR-2088's potential to inhibit starvation/stimuli-induced autophagic flux, coupled with its suitability for in vivo studies based on its pharmacokinetic properties.
PubMed: 38232465
DOI: 10.1016/j.ejmech.2023.116101
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.3 Å)
Structure validation

246704

PDB entries from 2025-12-24

PDB statisticsPDBj update infoContact PDBjnumon